19 June 2013
Keywords: merck, kgaa, buys, rights, stimuvax, germany-based, licensed
Article | 12 January 2009
Germany-based Merck KGaA has licensed the rights to Stimuvax, a vaccine in Phase III development for non-small cell lung cancer, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
12 January 2009
© 2013 thepharmaletter.com